We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: ovarian cancer
MedXY News
EnglishTag

ovarian cancer

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Harnessing Artificial Intelligence for Early Detection of Ovarian Cancer: Development and Validation of a Predictive Risk Model
AIearly detectionRisk Prediction

Harnessing Artificial Intelligence for Early Detection of Ovarian Cancer: Development and Validation of a Predictive Risk Model

By MedXY|Aug 31, 2026

A novel AI-driven risk prediction model for ovarian cancer demonstrates high accuracy and potential to improve early detection in screening settings.

Oral Anticoagulation Significantly Lowers Venous Thromboembolism Rates in Ovarian Cancer Patients on First-Line Chemotherapy: Insights from a Quality Improvement Project
Hematology-Oncology質改善
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
venous thromboembolism

Oral Anticoagulation Significantly Lowers Venous Thromboembolism Rates in Ovarian Cancer Patients on First-Line Chemotherapy: Insights from a Quality Improvement Project

By MedXY|Aug 25, 2026

A quality improvement initiative integrating oral anticoagulants reduced venous thromboembolism incidence in ovarian cancer patients undergoing first-line chemotherapy without increasing bleeding risks.

Trends in Incidence, Mortality, and Survival of Endometrial, Ovarian, and Cervical Cancers in Young Nordic Women: Insights from 40 Years of Registry Data
newsincidencesurvival

Trends in Incidence, Mortality, and Survival of Endometrial, Ovarian, and Cervical Cancers in Young Nordic Women: Insights from 40 Years of Registry Data

By MedXY|Aug 22, 2026

This article analyzes 40-year trends in incidence, mortality, and survival of endometrial, ovarian, and cervical cancers among Nordic women aged 0-49, highlighting evolving epidemiology and implications for age-specific prevention.

Niraparib Versus Platinum-Taxane Chemotherapy as Neoadjuvant Treatment in Advanced HR-Deficient Ovarian Cancer: Insights from the OPAL Phase 2 Trial
newsNiraparibneoadjuvant chemotherapy

Niraparib Versus Platinum-Taxane Chemotherapy as Neoadjuvant Treatment in Advanced HR-Deficient Ovarian Cancer: Insights from the OPAL Phase 2 Trial

By MedXY|Aug 21, 2026

The OPAL phase 2 trial compared neoadjuvant niraparib to standard platinum-taxane chemotherapy in newly diagnosed HR-deficient advanced ovarian cancer, showing inferior response rates with niraparib and a safety profile consistent with PARP

Evaluating CT-Based Models to Predict Residual Disease and Surgical Extent in Interval Debulking Surgery for Ovarian Cancer
newsovarian cancerinterval debulking surgery

Evaluating CT-Based Models to Predict Residual Disease and Surgical Extent in Interval Debulking Surgery for Ovarian Cancer

By MedXY|Aug 19, 2026

This study assesses the predictive accuracy of the MSKCC CT-based model for residual disease after neoadjuvant chemotherapy in advanced ovarian cancer, showing limited discrimination that improves with optimized clinical parameters. CT find

PRO-PLATINUM Trial: Probiotic Modulation of the Microbiome to Enhance Outcomes in Ovarian Cancer Chemotherapy
newsovarian cancermicrobiome

PRO-PLATINUM Trial: Probiotic Modulation of the Microbiome to Enhance Outcomes in Ovarian Cancer Chemotherapy

By MedXY|Aug 18, 2026

The PRO-PLATINUM trial evaluates a novel 5-strain probiotic’s effect on gut and vaginal microbiome composition and clinical outcomes in ovarian cancer patients undergoing platinum chemotherapy, assessing safety, feasibility, and trans

Long-Term Outcomes and Durability of Exceptional Responses to PARP Inhibitors in Recurrent Platinum-Sensitive Ovarian Cancer
newsExceptional responsePlatinum-sensitive

Long-Term Outcomes and Durability of Exceptional Responses to PARP Inhibitors in Recurrent Platinum-Sensitive Ovarian Cancer

By MedXY|Aug 18, 2026

This international study reveals that many patients with platinum-sensitive recurrent ovarian cancer achieve durable, progression-free survival exceeding 5 years on PARP inhibitors, even after treatment discontinuation, with a low risk of s

Family History Misses Actionable Germline Variants in Many Ovarian Cancer Patients Over 70
newsgermline testingovarian cancer

Family History Misses Actionable Germline Variants in Many Ovarian Cancer Patients Over 70

By MedXY|Aug 18, 2026

A large real-world registry study shows that ovarian cancer patients aged 70 and older still carry clinically actionable germline variants, often without a reported family history, supporting broader age-inclusive genetic testing.

Estrogen Therapy Linked to Improved Survival in Certain Ovarian Cancer Patients Under 60
newssurvival outcomesovarian cancer

Estrogen Therapy Linked to Improved Survival in Certain Ovarian Cancer Patients Under 60

By MedXY|Aug 18, 2026

Study shows post-diagnosis estrogen therapy improves survival in high-grade serous and clear cell ovarian cancers but may worsen outcomes in endometrioid subtypes, offering guidance for managing menopausal symptoms in younger survivors.

Real-world Evidence: Managing Platelet Counts in Ovarian Cancer Patients on First-Line Maintenance Niraparib
newsreal‑world evidenceplatelet monitoring

Real-world Evidence: Managing Platelet Counts in Ovarian Cancer Patients on First-Line Maintenance Niraparib

By MedXY|Aug 18, 2026

A US cohort study of 543 ovarian cancer patients revealed 37% experienced decreased platelets during niraparib maintenance. Onset typically occurred within 1 month but resolved rapidly with dose adjustments, resulting in low discontinuation

Lymph Node Isolated Tumor Cells in Ovarian Cancer: Clinically Significant or Pathological Incidentaloma?
newsDi căn hạch cổIsolated Tumor Cells

Lymph Node Isolated Tumor Cells in Ovarian Cancer: Clinically Significant or Pathological Incidentaloma?

By MedXY|Mar 13, 2026

A large-scale cohort study of over 15,000 patients reveals that isolated tumor cells (ITCs) in regional lymph nodes do not significantly impact short-term overall survival in epithelial ovarian cancer, despite higher prevalence in low-grade

Mobile App-Led Self-Acupressure: A Scalable Solution for Ovarian Cancer-Related Fatigue
newscancer-related fatiguedigital health

Mobile App-Led Self-Acupressure: A Scalable Solution for Ovarian Cancer-Related Fatigue

By MedXY|Feb 24, 2026

A phase 3 randomized clinical trial demonstrates that 6 weeks of mobile app-guided self-acupressure significantly and sustainably reduces fatigue in ovarian cancer survivors compared to usual care, providing a safe, low-cost digital health

A Proactive Approach to Ovarian Cancer: The New ESGO Consensus on Opportunistic Salpingectomy
newsopportunistic salpingectomyovarian cancer

A Proactive Approach to Ovarian Cancer: The New ESGO Consensus on Opportunistic Salpingectomy

By MedXY|Feb 9, 2026

The European Society of Gynaecological Oncology (ESGO) has released new consensus statements advocating for opportunistic salpingectomy—removing fallopian tubes during unrelated surgeries—to significantly reduce ovarian cancer risk without

Opportunistic Bilateral Salpingectomy Reduces Serous Ovarian Cancer Risk by Nearly 80 Percent
newsoncologyovarian cancer

Opportunistic Bilateral Salpingectomy Reduces Serous Ovarian Cancer Risk by Nearly 80 Percent

By MedXY|Feb 9, 2026

A large-scale population study confirms that removing fallopian tubes during unrelated pelvic surgeries reduces serous ovarian cancer risk by 78%, providing robust evidence for its use as a primary prevention strategy against high-grade ser

Beyond the Incessant Ovulation Hypothesis: How Menopausal Status and Birth Cohort Reshape Ovarian Cancer Risk
newsMenopauseoncology

Beyond the Incessant Ovulation Hypothesis: How Menopausal Status and Birth Cohort Reshape Ovarian Cancer Risk

By MedXY|Feb 6, 2026

A massive cohort study of 2.2 million women reveals that ovarian cancer risk factors vary significantly by menopausal status and birth year. While early menarche and low parity remain universal risks, the protective benefits of breastfeedin

newsovarian cancertrametinib

Biomarker-Driven Precision in Low-Grade Serous Ovarian Cancer: pERK and MAPK Mutations as Predictors of Trametinib Efficacy

By MedXY|Jan 12, 2026

Highlights Background: The Unique Challenge of Low-Grade Serous Ovarian Cancer Low-grade serous ovarian carcinoma (LGSOC)…

Atezolizumab Plus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer: Two Phase III Trials Fall Short of Practice‑Changing Benefit
newsatezolizumabbevacizumab

Atezolizumab Plus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer: Two Phase III Trials Fall Short of Practice‑Changing Benefit

By MedXY|Dec 8, 2025

Two randomized phase III trials tested adding atezolizumab to bevacizumab plus chemotherapy in recurrent ovarian cancer. Neither AGO‑OVAR 2.29/ENGOT‑ov34 (non‑platinum, platinum‑resistant) nor ATALANTE/ENGOT‑ov29 (platinum‑sensitive) met th

Defining Clinical Effectiveness of Risk-Reducing Early Salpingectomy in High-Risk BRCA Carriers: Insights from the PROTECTOR Cohort
Clinical UpdatesBRCAovarian cancer

Defining Clinical Effectiveness of Risk-Reducing Early Salpingectomy in High-Risk BRCA Carriers: Insights from the PROTECTOR Cohort

By MedXY|Sep 24, 2025

This article discusses the application of the estimand framework to evaluate clinical effectiveness of risk-reducing early salpingectomy with delayed oophorectomy in women with high ovarian cancer risk due to BRCA mutations, based on data f

Metformin in Gynecologic Cancers: A Comprehensive Review of Evidence in Cervical, Ovarian, and Endometrial Cancer
Clinical Updatescervical cancerEndometrial Cancer

Metformin in Gynecologic Cancers: A Comprehensive Review of Evidence in Cervical, Ovarian, and Endometrial Cancer

By MedXY|Oct 8, 2025

This review synthesizes recent evidence on metformin’s therapeutic and prognostic roles in cervical, ovarian, and endometrial cancers, highlighting randomized trials, meta-analyses, and clinical outcomes with a focus on progression-fr

Early Signs of Ovarian Cancer: Understanding the Three Common Areas of Itching and Common Misdiagnoses Among Women
newsearly symptomsovarian cancer

Early Signs of Ovarian Cancer: Understanding the Three Common Areas of Itching and Common Misdiagnoses Among Women

By MedXY|Oct 1, 2025

Ovarian cancer often presents subtle early symptoms like itching in the abdomen, genital area, and legs, which are frequently misinterpreted. Recognizing these signs is crucial for timely diagnosis and treatment.

1 / 2
12
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities